Abstract
This cross-sectional study explores the use of the brand-over-generic designation in the state Medicaid program formulary.
Introduction
The Medicaid Drug Rebate Program requires prescription drug manufacturers to provide rebates in exchange for guaranteed inclusion in state Medicaid formularies. For brand-name drugs, rebates prevent states from paying more than the best price available to private buyers, with additional rebates offsetting any price increases that outpace inflation. Since many brand-name drugs have substantial discounts for private payers and experience price increases exceeding rates of inflation, rebates for some products can grow to exceed the drug’s price.1 Thus, by the time generic drugs are introduced, the postrebate (net) cost of a brand-name drug can be lower than generic prices.2 In these cases, it is advantageous for states to use formularies to steer patients toward the brand-name version. To evaluate the extent to which states leverage this opportunity, we measured states’ use of brand-over-generic preferred formulary designations and the implications for medication use.
Methods
We obtained publicly available state Medicaid formularies as of January 2023, including states with specific lists of brand-over-generic preferred drugs and states designating 1 or more drugs as “brand preferred” in their preferred drug lists. We compiled lists of brand-over-generic drugs in each state by brand name and formulation. In accordance with 45 CFR §46.104, this cross-sectional study was exempt from ethics review because it was not human participant research. We followed the STROBE reporting guideline.
For drugs with brand-over-generic designations in at least 2 states, we used the 2023 Medicaid State Drug Utilization Data to measure the proportion of reimbursed brand-name units (eMethods in Supplement 1).3,4 Authorized generics (same products as brand-name drugs sold under generic labels) were not counted as brand-name use as they have different Medicaid rebate implications.5,6,7
We stratified reimbursement by fee-for-service (FFS) Medicaid vs managed care organizations (MCOs) because MCOs can lack the same direct financial incentives to prefer highly rebated drugs over generics.8 We used Wilcoxon rank sum and Kruskal-Wallis tests to compare the median proportion of brand-name use among states that had designated a drug with brand-over-generic preference, designated other drugs but not the drug of interest, or did not publish brand-over-generic designations.
Two-tailed P < .05 indicated statistical significance. Analyses were performed between January 1, 2024, and August 3, 2026, using R 4.6 (R Foundation for Statistical Computing).
Results
Fifteen of 51 state Medicaid programs (29.4%) published brand-over-generic designations, including 7 states with specific brand-over-generic lists and 8 states with brand-preferred designations on preferred drug lists. The number of designated drugs ranged from 14 in Wyoming to 131 in Utah. Of 294 drugs designated as brand-over-generic preference by 1 or more states, 157 (53.4%) were designated by only 1 state and none was designated by all 15 states (Figure 1).
Figure 1. Bar Graph of the Number of Drugs With Brand-Over-Generic Designation in 15 States in 2023.

States were included if they had designated lists of brand-over-generic drugs or preferred drug lists that designated 1 or more drugs as brand preferred, with independent generic versions marketed in the US in 2023. The bar colors represent the number of states that designated each drug as brand-over-generic.
Among 115 drugs designated by at least 2 states with independent generic competition, the median (IQR) share of brand-name use was higher in states that designated a drug as brand-over-generic (67.6% [8.3%-97.8%]) than states without such designation (0% [0%-10.5%]) or states without published designations (0.2% [0%-31.0%]) (P < .001). Among drugs with brand-over-generic designations, the median (IQR) share of brand-name use was higher in FFS Medicaid (88.3% [15.0%-100.0%]) than MCOs (25.6% [0%-87.8%]) (P < .001) (Figure 2).
Figure 2. Bar Graph of Median Brand-Name Use, by Brand-Over-Generic Designation and Reimbursement Source.

Figure includes 115 brand-name drugs with independent generic competition that were designated as brand-over-generic preferred by 2 or more states. Brand-name use was calculated as the share of innovator brand-name units among all units reimbursed (innovator brand name, authorized generic, and independent generic). Bars represent medians, and whiskers represent IQRs. FFS indicates fee-for-service, and MCO indicates managed care organization.
Discussion
We identified substantial variation in states’ use of formularies that prefer brand-name over generic drugs with substantial rebates because of Medicaid’s best-price and inflation rebate rules. When states used brand-over-generic designations, they effectively steered patients toward using the brand-name version, although steering was less effective when drugs were reimbursed by MCOs. These findings suggest major opportunities for some states to lower drug spending by adopting formulary strategies to favor highly rebated products.
The between-state variation may stem from limited knowledge or resources for states to identify drugs for which generic-version prices exceed the postrebate net prices of the branded version. This variation could be solved with greater transparency and better coordination among state Medicaid agencies. Because rebates are calculated by the Centers for Medicare & Medicaid Services (CMS) and the federal government shares Medicaid costs with states, CMS could support states by identifying eligible drugs. There is little to no cost-sharing for prescription drugs in Medicaid, but states should take measures to ensure that these designations do not adversely affect patients if there are higher copayments for brand-name vs generic prescriptions.
The limited responsiveness by MCOs to brand-preferred designations highlights another savings opportunity. Drugs reimbursed by MCOs are eligible for Medicaid rebates, but these rebates are paid directly to the states; MCOs lack incentives to account for rebates in formulary decisions.8,9 In response, some states have started carving prescription drugs out of MCO contracts or created unified formularies to maximize the use of highly rebated drugs.10
Study limitations include reliance on publicly reported state formulary data in a single year; some states may prefer brand-name over generic drugs without disclosing this publicly. Medicaid rebates are confidential, but we assumed brand-name drugs designated by 2 or more states were highly rebated. Despite these limitations, states have substantial opportunities to lower spending, including more consistent use of brand-preferred designations by state Medicaid programs and strategies to ensure that MCOs comply with these designations.
eMethods. Identification of Drugs With an Independent Generic
Data Sharing Statement
References
- 1.Rome BN, Kesselheim AS. Will ending the Medicaid drug rebate cap lower drug prices? JAMA Intern Med. 2021;181(8):1034-1035. doi: 10.1001/jamainternmed.2021.2696 [DOI] [PubMed] [Google Scholar]
- 2.Wang J, Lee CC, Kesselheim AS, Rome BN. Estimated Medicaid spending on original and citrate-free adalimumab from 2014 through 2021. JAMA Intern Med. 2023;183(3):275-276. doi: 10.1001/jamainternmed.2022.6299 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Medicaid Drug Rebate Program data . Centers for Medicare & Medicaid Services. Accessed February 3, 2026. https://data.medicaid.gov/dataset/0ad65fe5-3ad3-5d79-a3f9-7893ded7963a
- 4.Dusetzina SB, Keating NL, Huskamp HA. Authorized generics and their evolving role in prescription drug pricing and access. JAMA Intern Med. 2021;181(4):423-424. doi: 10.1001/jamainternmed.2020.8450 [DOI] [PubMed] [Google Scholar]
- 5.Centers for Medicare & Medicaid Services . Further recommendations on calculation of average manufacturer price of brand name and authorized generic drugs. Manufacturer Release No. 112. 2020. Accessed March 29, 2025. https://www.medicaid.gov/prescription-drugs/downloads/mfr-rel-112.pdf
- 6.Levy JF, Socal MP, Ballreich JM. Strategic manufacturer response to the Medicaid rebate cap removal. JAMA Health Forum. 2024;5(11):e243624. doi: 10.1001/jamahealthforum.2024.3624 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.El-Kilani ZS, Kulkarni S, Levy JF. Authorized generics as a manufacturer response to the Medicaid rebate cap removal. JAMA Health Forum. 2026;7(5):e260680. doi: 10.1001/jamahealthforum.2026.0680 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hernandez I, Gellad WF. Differences between managed care and fee-for-service Medicaid in the use of generics for high-rebate drugs: the cases of insulin glargine and glatiramer. J Manag Care Spec Pharm. 2020;26(2):154-159. doi: 10.18553/jmcp.2020.26.2.154 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Bendicksen L, Kesselheim AS. Anticipated efficiencies, real costs: Medicaid managed care organizations and the pharmacy benefit. J Manag Care Spec Pharm. 2022;28(3):354-361. doi: 10.18553/jmcp.2022.28.3.354 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hinton E, Williams E, Raphael J, et al. Amid unwinding of pandemic-era policies, Medicaid programs continue to focus on delivery systems, benefits, and reimbursement rates: results from an annual Medicaid budget survey for state fiscal years 2023 and 2024. KFF. November 14, 2023. Accessed July 1, 2025. https://www.kff.org/medicaid/50-state-medicaid-budget-survey-fy-2023-2024/
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
eMethods. Identification of Drugs With an Independent Generic
Data Sharing Statement
